MIP-1α和血小板第4因子对造血干细胞化疗药物损伤的保护作用

目的 研究巨噬细胞炎性蛋白 (MIP 1α)、血小板第 4因子 (PF4)及二者联合对造血干细胞化疗药物损伤的保护效应及其分子机制。方法 将骨髓、脐血单个核细胞及白血病细胞株HL 6 0分别予MIP 1α、PF4、MIP 1α +PF4、PBS预处理 48h ,再经柔红霉素 (DNR)孵育 2 4h后 ,用锥虫蓝 (台盼蓝 )拒染法测细胞活性 ,用流式细胞仪测细胞周期及CD34 + CD38- 细胞含量 ,细胞集落培养、免疫化学法测细胞P16、P2 7蛋白。结果 经MIP 1α及PF4预处理的骨髓和脐血单个核细胞 ,细胞活性、CD34+ CD38-细胞、集落形成能力均比对照组显著增加 (P <0 .0 5 )。MIP 1α、PF4组正常脐血及骨髓细胞S +G2 期百分率低于对照组 (P <0 .0 5 )。MIP 1α可上调细胞周期调控蛋白P16表达。PF4对P16、P2 7表达无影响。MIP 1α的保护作用强于PF4,但两者无协同效应。HL 6 0细胞P16、P2 7蛋白表达、细胞周期、细胞活性均不受MIP 1α、PF4的影响。结论 造血负调控因子MIP 1α、PF4能可逆性、选择性地保护正常造血细胞免受化疗药损伤 ,MIP 1α通过上调造血祖细胞G1 S期调控基因p16表达 ,使细胞阻滞于G0 期 ,提高细胞对周期特异性化疗药的耐受性。

金黄软膏外涂为主治疗化疗药物外渗性皮肤损伤

目的:观察冰敷后加金黄软膏外涂治疗化疗药物外渗性皮肤损伤的临床效果。方法:将100例化疗药物外渗皮肤损伤的病人随机分成两组,观察组(n=50)采用先冰敷1 h,然后外涂金黄软膏治疗。对照组(n=50)采用50%硫酸镁溶液湿敷治疗,并比较疗效。结果:治疗组有效率100%。对照组有效率74%。两组疗效比较有显著差异(P<0.05)。结论:先冰敷后外涂金黄软膏能有效治疗化疗药物外渗性皮肤损伤。

三种治疗化疗药物渗漏性损伤的方法的疗效观察与研究

目的：通过对我院肿瘤科病人三种治疗化疗药物渗漏性损伤的临床疗效观察和研究，探讨治疗化疗药物渗漏性损伤的行之有效的方法。方法：对我院肿瘤科2001年1月-2007年1月有化疗药物渗漏性损伤的病人按时间先后依次随机分为ABC组，并将有局部组织肿胀，静脉炎和浅层组织坏死患者均衡的分配到ABC三组中。A组（38例）为发现渗漏后用50％MgSO4持续加压冷敷24h后热敷；B组（40例）为发现化疗药物渗漏后立即用2％山莨菪碱注射液1～2ml局部封闭后用50％MgSO4持续加压冷敷24h后热敷；C组（39例）为发现化疗药物渗漏后用2％山莨菪碱注射液1～2ml加1％利多卡因1～3ml局部封闭治疗后用50％MgSO4持续加压冷敷24h后热敷。结果：A组一周总有效率为52．63％；B组一周总有效率为80％；C组一周总有效率为94．87％。结论：2％山莨菪碱注射液1-2ml＋1％利多卡因1～3ml局部封闭治疗后用50％MgSO4持续加压冷敷24h后热敷是治疗化疗药物渗漏性损伤的行之有效的方法。

肿瘤病人医源性皮肤损伤的治疗

目的:探讨肿瘤病人医源性皮肤损伤的治疗方法.方法:对1999年8月～2002年2月,采用湿润烧伤膏(MEBO)治疗的12例病例进行回顾性总结,主要分析指标为损伤原因,原发病,病变范围,愈合时间等.结果:Ⅱ、Ⅲ度创面一般在12天～28天愈合,个别病例40天后愈合或植皮治愈.结论:肿瘤病人放射性或化学治疗造成的损伤传统疗法愈合缓慢,MEBO不仪有良好的止痛作用,同时可加速创面愈合.

Effectiveness of hepatoprotective medication during cancer chemotherapy

Objective Chemotherapy may cause drug-induced liver damage and studying the effectiveness of hepatoprotective substances in the clinical context is still warranted. We assessed the effectiveness of three commonly used natural substances for liver protection in East Asia. Methods： Retrospectively, we collected all medical records during a period of three years of cancer patients that underwent chemotherapy treatment and received glutathione, magnesium isoglicyrrhyzinate or polyene phosphatidylcholine at a Chinese integrative medicine hospital. Liver enzymes before and after one treatment cycle were detected. Paired t-test, chi-square, Snedcor＇s F distribution and ANOVA were used to analyze data. Results： 98 individuals were eligible for inclusion. After treatment, in the glutathione group, there were lower values in alanine aminotransferase （P 〈 0.05） and aspartate aminotransferase （P 〈 0.05）. There was also a lower level of liver injury in patients （P 〈 0.05）. In the magnesium isoglycyrrhizinate group there were lower values in total protein （P 〈 0.05）, alkaline phosphatase （P 〈 0.05） and gamma glutamyl transpeptidase values （P 〈 0.05）. There was also a lower level of liver injury in patients after treatment （P 〈 0.05）. In the polyene phosphatidylcholine group, there were no lower values of interest, including those of liver injury in patients （P 〉 0.05）. Conclusion： Glutathione and magnesium isoglicyrrhyzinate may be similarly effective in preserving liver function and preventing drug-induced liver injury in cancer patients undergoing chemotherapy. Polyene phosphatidylcholine may have no significant activity in protecting liver function and preventing drug-induced liver injury in advanced cancer patients undergoing chemotherapy. Since elevated glutathione levels may increase the antioxidant capacity and the resistance to oxidative stress by cancer cells, it is plausible to conclude that maintenance of high intracellular levels of glutathione could be critical for metastatic cells growth.

A novel bone marrow targeted gadofullerene agent protect against oxidative injury in chemotherapy

Chemotherapy as an effective cancer treatment technique has been widely used in tumor therapy. However, it is still a challenge to overcome the serious side effects of chemotherapy, especially for its myelotoxicity. Here we report a novel strategy using the water soluble gadofullerene nanocrystals（GFNCs） to protect against chemotherapy injury in hepatocarcinoma bearing mice, which was induced by the commonly chemotherapeutic agent cyclophosphamide（CTX）.The GFNCs were revealed to specifically accumulate in the bone marrow after intravenously injecting to mice and they exhibited excellent radical scavenging function, resulting in a prominent increase of mice blood cells and pathological improvements of the primary organs in the GFNCs（15 mg kg-（-1））treated mice after the CTX（60 mg kg-（-1）） therapy. Moreover,the GFNCs maintained and even strengthened the antineoplastic activity of the CTX agent. Therefore, the GFNCs would be the promising chemoprotective agents in chemotherapy based on their high efficiency, low toxicity and metabolizable property.